Aileron Therapeutics has been granted a patent for compositions containing modified caveolin-1 peptides for treating lung infections and injuries, especially lung fibrosis. The patent includes a specific peptide sequence that is soluble in water. GlobalData’s report on Aileron Therapeutics gives a 360-degree view of the company including its patenting strategy. Buy the report here.

Smarter leaders trust GlobalData


Data Insights Aileron Therapeutics Inc - Company Profile

Buy the Report

Data Insights

The gold standard of business intelligence.

Find out more

According to GlobalData’s company profile on Aileron Therapeutics, Peptide pharmacophores was a key innovation area identified from patents. Aileron Therapeutics's grant share as of February 2024 was 30%. Grant share is based on the ratio of number of grants to total number of patents.

Modified cav-1 peptides for lung infection and injury treatment

Source: United States Patent and Trademark Office (USPTO). Credit: Aileron Therapeutics Inc

A recently granted patent (Publication Number: US11905336B2) discloses a novel peptide with the amino acid sequence aaEGKASFTTFTVTKGSaa-NH2 or Ac-aaEGKASFTTFTVTKGSaa-NH2, where "a" represents D-alanine. The peptide is designed to be soluble in aqueous solutions and may include non-standard amino acid substitutions. Additionally, the peptide may have modifications such as an N-terminal addition or acylation, enhancing its properties.

Furthermore, the patent claims cover variations of the peptide sequence, including substitutions like ornithine for lysine and modifications like acylation. The composition containing the peptide is required to be at least 98% pure and can be formulated as a dry powder. The patent also specifies a peptide consisting solely of Ac-aaEGKASFTTFTVTKGSaa-NH2. These claims highlight the unique characteristics and potential applications of the peptide in various fields, emphasizing its solubility, purity, and formulation options.

To know more about GlobalData’s detailed insights on Aileron Therapeutics, buy the report here.

Data Insights


The gold standard of business intelligence.

Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.


GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData Patent Analytics tracks bibliographic data, legal events data, point in time patent ownerships, and backward and forward citations from global patenting offices. Textual analysis and official patent classifications are used to group patents into key thematic areas and link them to specific companies